Aesthetic plastic surgery · 2025
Essential Pharmaceutical Drugs in the Filler Emergency Kit.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Madero-Pérez Javier, Gil-Martinez Marta, Muñoz-Gonzalez Cristina, Martin-Marfil Paula, Fakih-Gomez Nabil
Аннотация
INTRODUCTION: The rise in clinical procedures utilizing dermal fillers necessitates preparedness for potential emergencies. Effective management of complications arising from filler use, including vascular occlusions and allergic reactions, hinges on the availability of the appropriate pharmacological supplies.
METHODS: A two-tiered search in PubMed and Google Scholar was conducted to identify essential drugs for dermal filler emergencies. An initial 10-year review used keywords "Dermal Fillers," "vascular occlusion," and "hyaluronidase," followed by a targeted search on "Resuscitation guidelines," "anaphylaxis management," "allergy fillers," and "lidocaine." This article outlines the critical drug inventory for emergency kits to manage filler-related complications effectively.
RESULTS: An ORA classification system (Obligatory, Recommended, Advisable) is introduced to categorize essential drugs according to urgency and clinical necessity. The required drugs are grouped based on their application in cases of vascular occlusion without ocular involvement, vascular occlusion with ocular involvement, anaphylactic reactions, cardiopulmonary resuscitation and hemodynamic disorders, delayed reactions, and aseptic, oxygen, and topical treatments. Additionally, the importance of meticulous drug inventory management-including tracking of stock entry, exit, and expiration dates-is emphasized to reduce the risk of shortages.
CONCLUSION: Ensuring that filler emergency kit is well stocked with vital pharmacological supplies is imperative for effective emergency management during filler procedures. Adopting systematic inventory practices and utilizing the ORA classification can enhance preparedness and patient safety.
LEVEL OF EVIDENCE V: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
METHODS: A two-tiered search in PubMed and Google Scholar was conducted to identify essential drugs for dermal filler emergencies. An initial 10-year review used keywords "Dermal Fillers," "vascular occlusion," and "hyaluronidase," followed by a targeted search on "Resuscitation guidelines," "anaphylaxis management," "allergy fillers," and "lidocaine." This article outlines the critical drug inventory for emergency kits to manage filler-related complications effectively.
RESULTS: An ORA classification system (Obligatory, Recommended, Advisable) is introduced to categorize essential drugs according to urgency and clinical necessity. The required drugs are grouped based on their application in cases of vascular occlusion without ocular involvement, vascular occlusion with ocular involvement, anaphylactic reactions, cardiopulmonary resuscitation and hemodynamic disorders, delayed reactions, and aseptic, oxygen, and topical treatments. Additionally, the importance of meticulous drug inventory management-including tracking of stock entry, exit, and expiration dates-is emphasized to reduce the risk of shortages.
CONCLUSION: Ensuring that filler emergency kit is well stocked with vital pharmacological supplies is imperative for effective emergency management during filler procedures. Adopting systematic inventory practices and utilizing the ORA classification can enhance preparedness and patient safety.
LEVEL OF EVIDENCE V: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .